Koelis, SAS ("Koelis" or the "Company", a leader and innovator in MRI-ultrasound fusion guidance for prostate cancer interventions, recently announced that the Centers for Medicare & Medicaid ...

High-resolution microultrasonography-guided biopsy was non-inferior to MRI fusion-guided biopsy for detecting clinically significant prostate cancer (detection rates, 47.1% and 42.6%, respectively), a ...

Prostate cancer is the second-leading cause of death among American men, killing one in 44. In the United States, 3.3 million men are survivors of prostate cancer, and the risk for developing the ...

A large screening trial showed that using prostate-specific antigen density (PSAD) before MRI prevented overdiagnosis and lowered resource use while preserving the detection of clinically significant ...

Dec. 15, 2025 — For decades, when tests suggested that a man might have prostate cancer, the next step was usually a biopsy. The procedure, where a doctor uses a thin needle to collect prostate ...

Microultrasonography for prostate biopsy detected clinically significant cancer at rates comparable to MRI-guided approaches. Detection rates for clinically insignificant cancers did not differ among ...

Every September, countries across the world observe Prostate Cancer Awareness Month to highlight the importance of prostate health and early detection. It was first declared by the American Foundation ...

Profound Medical ( ($TSE:PRN) ) has shared an announcement. Profound Medical announced that The Johns Hopkins Hospital has performed its first ...

ISMI offers a radiologist-led Full-Body MRI in Montreal to identify life-saving findings, detect health risks, and support ...